* CalciMedica Inc is expected to show no change in quarterly revenue when it reports results on November 7 (estimated) for the period ending September 30 2024
*
* LSEG's mean analyst estimate for CalciMedica Inc is for a loss of 50 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for CalciMedica Inc is $16.00, above its last closing price of $3.54.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.52 -0.53 -0.36 Beat 31.6
Mar. 31 2024 -0.69 -0.67 0.01 Beat 101.5
Dec. 31 2023 -0.72 -0.87 -0.23 Beat 73.6
Sep. 30 2023 -1.14 -1.14 -0.82 Beat 28.1
Jun. -1.05 -1.04 -1.11 Missed -6.2
30 2023
Jan. 1 0001 -0.73 -0.73 -23.43 Missed -3,109
.6
Sep. 30 2022 -6.16 -6.44 Missed -4.5
This summary was machine generated November 6 at 14:27 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments